formylchromone

structure in first source

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Carcinogenesis 08/05/2014 - "Formylchromone exhibits salubrious effects against nitrosodiethylamine mediated early hepatocellular carcinogenesis in rats."
2.	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/01/2008 - "PTP1B inhibitors such as Formylchromone derivatives, 1, 2-Naphthoquinone derivatives and Oxalyl aryl amino benzoic derivatives may eventually find an important clinical role as insulin sensitizers in the management of Type-II Diabetes and metabolic syndrome. "
3.	Obesity 08/04/2003 - "The potency and selectivity of the formylchromone derivatives expecting further improvements provides a novel pharmacophore for the design of drugs for the treatment of type 2 diabetes and obesity."
4.	Type 2 Diabetes Mellitus (MODY) 08/04/2003 - "The potency and selectivity of the formylchromone derivatives expecting further improvements provides a novel pharmacophore for the design of drugs for the treatment of type 2 diabetes and obesity."

1.	Insulin (Novolin)
2.	Diethylnitrosamine (N-Nitrosodiethylamine)